# Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer

> **NCT00327171** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 218 (actual)

## Conditions studied

- Neoplasms
- Cancer of the Ovary

## Interventions

- **DRUG:** Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
- **DRUG:** Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)

## Key facts

- **NCT ID:** NCT00327171
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2008-04
- **Final completion:** 2010-03
- **Target enrollment:** 218 (ACTUAL)
- **Last updated:** 2016-06-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00327171

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00327171, "Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00327171. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*